Regulus, Alnylam and Isis Announce U.S. Allowance of Tuschl III Patent Application Covering miR-21

Business Wire 1/25/09

The newly allowed claims cover miR-21, a microRNA that has been linked to a variety of diseases, including cancer, fibrosis, and heart disease. The claims additionally encompass single-stranded and double-stranded antisense compounds complementary to miR-21. The allowance of this second Tuschl III patent in the U.S. extends the scope of this patent estate, which has already yielded patents directed to miR-122 in the U.S. (U.S. Patent No. 7,232,806), Australia (Australia Patent No. 2002 347 035), and Japan (Japan Patent No. 4 371 812). (read more…)

Incoming search terms for this article:

• isis mirna
• tuschl iii
• patent regulus
• miRNA-21 patent
• miR-21 patent
• Regulus miRNA patent
• regulus therepeutics Tuschl
• tuschl and patent and miRNA diagnostic
• tuschl cancer
• tuschl iii patent

Related posts:

1. Marina Biotech Announces Allowance of Patent Covering DiLA2 Delivery of microRNAs
2. Regulus Strengthens Patent Coverage of miR-122
3. USPTO Notice of Allowance for the Diagnostic Application of an Important Cancer-Related miRNA
4. Alnylam Pharmaceuticals & Regulus Therapeutics in the News
5. Marina Biotech Receives Notice of Acceptance for Patent Broadly Covering Its Unlocked Nucleobase Analog (UNA) Technology

Tagged as: Alnylum, Isis, microrna, mir-21, patent, Regulus Therapeutics, Tuschl